Cargando…

Risks of trastuzumab‐related cardiotoxicity in breast cancer patients in Taiwan

AIMS: In contrast to Western patients with breast cancer, Asian patients are relatively younger at diagnosis, and most are free from traditional cardiovascular risk factors. Despite trastuzumab‐related major adverse cardiac and cerebrovascular event (MACCE) being reported, its incidence and predicto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Wei‐Ting, Chen, Po‐Wei, Lin, Hui‐Wen, Lin, Sheng‐Hsiang, Li, Yi‐Heng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712795/ https://www.ncbi.nlm.nih.gov/pubmed/34480791 http://dx.doi.org/10.1002/ehf2.13591

Ejemplares similares

Risks of Aromatase Inhibitor-Related Cardiotoxicity in Patients with Breast Cancer in Asia
por: Chang, Wei-Ting, et al.
Publicado: (2022)

Trastuzumab Cardiotoxicity in Patients with Breast Cancer
por: Freitas, Aguinaldo Figueiredo, et al.
Publicado: (2014)

Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer
por: Marinko, Tanja, et al.
Publicado: (2014)

Risk of Trastuzumab-Related Cardiotoxicity in Early Breast Cancer Patients: A Prospective Observational Study
por: Xue, Jian, et al.
Publicado: (2014)

The association between tyrosine kinase inhibitors and fatal arrhythmia in patients with non-small cell lung cancer in Taiwan
por: Chang, Wei-Ting, et al.
Publicado: (2023)

Assessment of Tyrosine Kinase Inhibitors and Survival and Cardiovascular Outcomes of Patients With Non–Small Cell Lung Cancer in Taiwan
por: Chang, Wei-Ting, et al.
Publicado: (2023)

Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis
por: Jawa, Zeeshan, et al.
Publicado: (2016)

Detection of Subclinical Trastuzumab-Induced Cardiotoxicity in Patients with Breast Cancer
por: dos Santos, Marília Harumi Higuchi
Publicado: (2013)

Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy
por: Méndez-Valdés, Gabriel, et al.
Publicado: (2023)

The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment
por: Lin, Mengmeng, et al.
Publicado: (2022)

Coq10 for preventing cardiotoxicity in breast cancer patients treated with trastuzumab
por: Al-Hammadi, Nawal, et al.
Publicado: (2023)

Association of Statin Use With Cancer- and Noncancer-Associated Survival Among Patients With Breast Cancer in Asia
por: Chang, Wei-Ting, et al.
Publicado: (2023)

Acute Cardiotoxicity With Concurrent Trastuzumab and Hypofractionated Radiation Therapy in Breast Cancer Patients
por: Sayan, Mutlay, et al.
Publicado: (2019)

Trastuzumab-related cardiotoxicity: what do we know in 2020?
por: Liu, Jia, et al.
Publicado: (2020)

A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients
por: Matos, Erika, et al.
Publicado: (2016)

Early Cardiotoxicity after Adjuvant Concomitant Treatment with Radiotherapy and Trastuzumab in Patients with Breast Cancer
por: Marinko, Tanja, et al.
Publicado: (2018)

Mild Cardiotoxicity and Continued Trastuzumab Treatment in the Context of HER2-Positive Breast Cancer
por: de la Brassinne Bonardeaux, Orianne, et al.
Publicado: (2023)

Type IIB DNA topoisomerase is downregulated by trastuzumab and doxorubicin to synergize cardiotoxicity
por: Jiang, Jiangsong, et al.
Publicado: (2017)

The influence of steroid receptor status on the cardiotoxicity risk in HER2-positive breast cancer patients receiving trastuzumab
por: Huszno, Joanna, et al.
Publicado: (2015)

Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario
por: Shrivastva, Sarita, et al.
Publicado: (2023)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Valvular heart disease as a possible predictor of trastuzumab-induced cardiotoxicity in patients with breast cancer
por: Sato, Akihiko, et al.
Publicado: (2019)

Cardioncological Approach for Trastuzumab Therapy in Breast Cancer Patients With Cardiotoxicity: Impact on Adherence and Clinical Outcome
por: Fabiani, Iacopo, et al.
Publicado: (2020)

NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients
por: Blancas, Isabel, et al.
Publicado: (2020)

Trastuzumab-induced cardiotoxicity in early breast cancer over a 10-year period in Uruguay
por: Castillo, Cecilia, et al.
Publicado: (2022)

Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study
por: Kaboré, Elisé G., et al.
Publicado: (2019)

Long-term irreversible trastuzumab-induced cardiotoxicity for metastatic breast cancer in a patient without cardiac risk factors
por: Tanaka, Satoru, et al.
Publicado: (2017)

How can clinical research help our understanding of trastuzumab-related cardiotoxicity?
por: Lyons, Tomás G., et al.
Publicado: (2015)

A Case of Trastuzumab-Associated Cardiomyopathy Presenting as an Acute Coronary Syndrome: Acute Trastuzumab Cardiotoxicity
por: Hidalgo, Sylvana, et al.
Publicado: (2013)

High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy
por: Katsurada, Kenichi, et al.
Publicado: (2014)

Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report
por: Minichillo, Santino, et al.
Publicado: (2017)

Biomarker panel for early screening of trastuzumab -induced cardiotoxicity among breast cancer patients in west virginia
por: Pillai, Sneha S., et al.
Publicado: (2022)

The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis
por: Wu, Yi-Ying, et al.
Publicado: (2016)

An Initial Evaluation of Human Plasma cMLC-1: A Potential Protein Biomarker for Trastuzumab-Induced Cardiotoxicity, Breast Cancer Screening and Progression
por: Yu, Ling, et al.
Publicado: (2022)

Risk Factors Associated with Trastuzumab-induced Cardiotoxicity in Patients with Human Epidermal Growth Factor Receptor 2-positive Breast Cancer
por: Abdel-Razaq, Wesam, et al.
Publicado: (2019)

Doxorubicin‐induced and trastuzumab‐induced cardiotoxicity in mice is not prevented by metoprolol
por: Nicol, Martin, et al.
Publicado: (2021)

Ginsenoside Rg2 Attenuated Trastuzumab-Induced Cardiotoxicity in Rats
por: Liu, Guang, et al.
Publicado: (2022)

Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
por: Eaton, Holden, et al.
Publicado: (2023)

Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab
por: Zhou, Shijie, et al.
Publicado: (2023)

Thyroid disorders and breast cancer risk in Asian population: a nationwide population-based case–control study in Taiwan
por: Weng, Chien-Hsiang, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rk9qvrnq3hg2crsmnjku20uj8u